Novavax (NVAX)
(Delayed Data from NSDQ)
$15.03 USD
-0.22 (-1.44%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.04 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Novavax, Inc. [NVAX]
Reports for Purchase
Showing records 281 - 296 ( 296 total )
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q2:12 Update - Next Up, Pandemic Flu Data Q4 and RSV Phase II Trial Start - Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Novavax Phase II Seasonal Influenza Trial - Primary Endpoints Achieved
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
July 2012 Potential Catalysts & Milestones - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q1:12 - Flu Program Progressing Well as RSV Takes Center Stage - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q4:11 - Continued Execution on Influenza Vaccine Program
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase I RSV Data, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Update from our Life Sciences Management Access Conference & Q2 Results; Attention Shifts to RSV Data
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
2Q11 Results Driven by Better Contract Revenues
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q1:11 Update - Seasonal Trivalent Phase II To Start in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Q4:10 Update - BARDA Award and Partnership Underappreciated, in our Opinion
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Novavax, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $6 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G